Clonegene generates antibodies that selectively recognize proteins that are aberantly expressed in human tumors and thus can be used in the cellular diagnosis and therapy of cancer. For example, knowledge that a significant number of tumor cells harbor particular mutations prompts the physician to treat the cancer with a therapeutic agent that selectively inactivates the pathways perturbed by the mutant protein.
By using a proprietary algorithm to design peptide antigens, our antibodies are very high affinity and are excellent reagents for the detection of proteins in archival FFPE sections. The current catalogue features antibodies that have been used in published studies to identify biomarkers in SCLC, NSCLC, and Breast cancers. The antibodies currently in production are specifically directed against the mutant peptides found by the recent next generation DNA sequence studies.
Importantly, our antibodies have also proven useful for many other life science utilities including western blotting, immunoprecipitation, CHIP genomic analysis and RNA immunoprecipitation (CLIP).
We also provide excellent anti-Tag, loading control and isotype control antibodies.
Generation of monoclonal antibodies for cancer research and therapy
CLONEGENE designs and generates anti-peptide antibodies to proteins of fundamental and therapeutic interest. By using a proprietary algorithm to design peptide antigens, our antibodies are very high affinity and are excellent reagents for western blotting, immunoprecipitation, CHIP genomic analysis and immunohistochemistry on archival FFPE sections. Importantly, we provide expertise to the customer that permits validation of antibody target specificity by siRNA knockdown of the antigen. From your idea to validated rabbit affinity purified antibody in 3 months , starting at $3,000. Contact us for a quote on your project
Clonegene LLC has not received any reviews.
Clonegene LLC has not received any endorsements.